Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

NCT: NCT07266584 · RECRUITING

NCT IDNCT07266584
StatusRECRUITING
Start Date2026-03-12
Completion2031-03-01

Brief Summary

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa). Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.

Frequently Asked Questions

What is Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration?

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration is a clinical trial registered under NCT07266584. Current status: RECRUITING.

What is the status of NCT07266584?

The current status of NCT07266584 (Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration) is: RECRUITING.

When did Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration start?

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration started on 2026-03-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑